Noxopharm Ltd (ASX:NOX, OTC:NOXOF) chief executive officer Dr Gisela Mautner joins Proactive alongside Associate Professor Michael Gantier from the Hudson Institute of Medical Research to discuss their partnering on the SOF-VAC mRNA vaccine enhancer. They’re investigating the potential for Sofra oligonucleotides to limit the inflammatory side effects associated with mRNA therapeutics and vaccines. They say the ability of the oligonucleotides to reduce inflammation opens up new possibilities for the treatment of many diseases.
Noxopharm talks partnership with Hudson Institute of Medical Research
